Ability Pharmaceuticals develops new drug candidates through clinical proof-of-concept, to later license them to pharmaceutical companies for further development and marketing. 

Ability Pharmaceuticals is in-licensing new drug candidates from research institutions and other biotech and pharma companies, focusing in compounds that could be ready to start regulatory preclinical development in less than one year.

Ability Pharmaceuticals also establishes research collaborations with academic institutions to provide the company with an engine to generate new drug candidates and to build a competitive development pipeline.


In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with the US company SciClone Pharmaceuticals to develop and market the product in Greater China, with upfront and milestone payments over $ 20 M



If you are interested in learning more on our products in development or you have a licensing opportunity which could be of our interest, please contact us.